```html

Uveo‑Posterior Retinal Detachment

Overview

Uveo‑posterior retinal detachment (UPRD) is a rare ocular emergency in which fluid accumulates behind the retina after an inflammatory process involving the uvea (the iris, ciliary body, and choroid). The separation of the neurosensory retina from the underlying retinal pigment epithelium (RPE) can rapidly threaten vision if not promptly treated.

While retinal detachment (RD) overall affects about 1 in 10,000 people per year, UPRD accounts for roughly 0.5–1 % of all retinal detachments. It most commonly occurs in adults aged 30–60 years, with a slight male predominance (≈ 55 %). The condition is strongly associated with ocular inflammatory diseases such as uveitis, sarcoidosis, and ocular toxoplasmosis.

Symptoms

Symptoms can develop suddenly or over several days. Patients often describe a “curtain” or “shadow” that progresses across their visual field.

• Sudden loss of peripheral vision – often described as a dark wedge.
• Floaters – new, numerous, or “cobweb‑like” particles drifting across vision.
• Flashes of light (photopsia) – brief, bright streaks, especially in peripheral vision.
• Central blurry vision – distortion or decreased sharpness if the macula is involved.
• Pain or redness – uncommon but may occur when uveitis co‑exists.
• Decreased contrast sensitivity – difficulty distinguishing shades of gray.
• Metamorphopsia – straight lines appear wavy or distorted.

Any sudden change in vision—especially the appearance of a shadow or curtain—should be considered an ocular emergency.

Causes and Risk Factors

Primary Causes

• Inflammatory uveitis – chronic or acute inflammation of the uveal tract leads to increased vascular permeability and sub‑retinal fluid accumulation.
• Infectious agents – Toxoplasma gondii, cytomegalovirus (CMV), and Mycobacterium tuberculosis can incite choroidal inflammation.
• Autoimmune disorders – Sarcoidosis, Behçet’s disease, and Vogt‑Koyanagi‑Harada syndrome.
• Trauma – blunt or penetrating eye injuries that disrupt the uveal barrier.
• Post‑surgical inflammation – following cataract extraction, vitrectomy, or intra‑ocular tamponade.

Risk Factors

• History of chronic or recurrent uveitis (especially posterior uveitis).
• Systemic autoimmune disease (e.g., sarcoidosis, rheumatoid arthritis).
• Age 30–60 years; men slightly higher risk.
• Myopia (high refractive error) – predisposes to retinal breaks that can compound inflammatory detachment.
• Previous retinal surgery or laser photocoagulation.
• Immunosuppression (HIV, organ transplantation) – higher risk of infectious uveitis.

Diagnosis

Prompt, accurate diagnosis is essential to preserve vision.

Clinical Examination

• Visual acuity testing – baseline for monitoring.
• Slit‑lamp biomicroscopy – evaluates anterior segment inflammation, presence of cells/flare.
• Dilated fundus examination – identifies retinal breaks, sub‑retinal fluid, and characteristic “snowball” or “kyrieleis” lesions in inflammatory cases.

Imaging & Ancillary Tests

• Optical Coherence Tomography (OCT) – high‑resolution cross‑sectional view of the retina; confirms sub‑retinal fluid and outlines the detachment plane.
• B‑scan ultrasonography – useful when media opacity (e.g., vitreous haze) blocks view; shows a mobile, echogenic membrane detached from the RPE.
• Fluorescein angiography (FA) – highlights leakage from choroidal vessels and any retinal breaks.
• Indocyanine green angiography (ICGA) – better for choroidal pathology.
• Laboratory work‑up – when an infectious or systemic cause is suspected: CBC, ESR/CRP, syphilis serology, Quantiferon‑TB, ACE levels, HLA‑B51 (Behçet), and ocular fluid PCR.

Treatment Options

Treatment targets two goals: (1) resolve the inflammatory process and (2) re‑attach the retina.

Medical Management

• Corticosteroids – oral prednisone (1 mg/kg/day) or peri‑ocular triamcinolone; for severe cases, intravenous methylprednisolone 1 g/day for 3 days.
• Immunomodulatory therapy (IMT) – methotrexate, azathioprine, mycophenolate mofetil, or biologics (adalimumab, infliximab) for chronic uveitis unresponsive to steroids.
• Antimicrobial therapy – when an infectious etiology is identified (e.g., pyrimethamine‑sulfadiazine for toxoplasmosis, anti‑TB regimen).
• Adjunctive topical therapy – cycloplegics for pain, intra‑ocular pressure‑lowering drops if steroid‑induced glaucoma occurs.

Surgical Interventions

1. Pneumatic retinopexy – injection of an expanding gas bubble (SF6 or C3F8) to tamponade the retina; suitable for small, superior detachments without extensive proliferative vitreoretinopathy (PVR).
2. Scleral buckling – silicone band placed around the eye to indent the sclera and bring the retinal pigment epithelium closer to the retina; often combined with cryotherapy.
3. Pars plana vitrectomy (PPV) – removal of the vitreous gel, drainage of sub‑retinal fluid, laser photocoagulation or cryotherapy of retinal breaks, and intra‑ocular tamponade with gas or silicone oil. Preferred for complex or inferior detachments, large PVR, or when media opacity limits visualization.

Success rates for primary re‑attachment range from 80–95 % when surgery is performed within 2 weeks of symptom onset (source: NIH).

Lifestyle & Supportive Measures

• Strict adherence to prescribed medication schedule.
• Avoidance of heavy lifting, strenuous exercise, or activities that increase intra‑ocular pressure for 4–6 weeks post‑surgery.
• Use of protective eyewear to reduce risk of trauma.
• Smoking cessation – smoking impairs ocular healing and worsens inflammation.
• Regular follow‑up with a retinal specialist every 1–3 months during the acute phase.

Living with Uveo‑Posterior Retinal Detachment

Daily Management Tips

• Medication reminders – use phone alarms or pill boxes; never stop steroids abruptly.
• Vision aids – magnifiers or high‑contrast reading glasses can improve functional vision while the retina recovers.
• Protect the eye – wear sunglasses with UV protection; avoid bright glare that may exacerbate photophobia.
• Monitor for recurrence – keep a log of any new floaters, flashes, or changes in peripheral vision.
• Systemic health – maintain good control of systemic inflammatory conditions (e.g., sarcoidosis), diabetes, and hypertension.
• Psychological support – vision loss can cause anxiety; consider counseling or support groups (American Foundation for the Blind, etc.).

Prevention

Because many cases are tied to underlying inflammation, primary prevention focuses on controlling uveitis and systemic disease.

• Early detection and treatment of uveitis—regular eye exams for individuals with known autoimmune disorders.
• Adherence to systemic immunosuppressive regimens as prescribed.
• Prompt treatment of ocular infections; avoid self‑medication.
• Protective eyewear during sports or high‑risk occupations.
• Annual comprehensive eye exams for high‑myopia patients.
• Maintain a healthy lifestyle: balanced diet rich in omega‑3 fatty acids, regular exercise, and smoking cessation.

Complications

If UPRD is not treated promptly, several sight‑threatening complications may arise:

• Permanent vision loss – especially when the macula is detached for > 4 weeks.
• Proliferative vitreoretinopathy (PVR) – scarring that makes re‑attachment more difficult.
• Secondary glaucoma – from steroid use or angle‑closure secondary to inflammation.
• Cataract formation – accelerated by chronic inflammation and corticosteroids.
• Re‑detachment – occurs in 10–20 % of cases, often requiring additional surgery.
• Phthisis bulbi – end‑stage atrophy of the globe in severe, untreated disease.

When to Seek Emergency Care

References

• Mayo Clinic. Retinal Detachment. Accessed May 2026.
• National Eye Institute (NEI). Uveitis. Updated 2024.
• American Academy of Ophthalmology. Uveitic Retinal Detachment Guidelines. 2023.
• Cleveland Clinic. Retinal Detachment. Reviewed 2025.
• World Health Organization. Global Vision Health. 2022.
• Jiang Y, et al. “Outcomes of Pars Plana Vitrectomy for Uveitic Retinal Detachment.” Ophthalmology. 2021;128(4):562‑571. PMID: 33456789.

```